1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sunrest Lifescience Limited

Sunrest Lifescience Limited

NNSE:SUNREST
35.00
INR
-2.65
(-7.04%)
277.30MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
20.63
30.6
47.67
46.61
73.77
60.33
165.05
- -
Basic EPS, GAAP
0.07
0.32
1.51
3.96
0.56
3.62
9.59
- -
Free Cash Flow per Basic Share
-1.75
-0.02
-1.77
2.21
-37.06
2.8
-17.64
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.25
0.57
2.08
6.04
27.5
31.62
39.6
31.62
Tangible Book Value per Share
0.25
0.57
2.08
6.04
27.48
31.6
39.42
31.6
Basic Weighted Avg Shares
5
5
5
5
4
6
4
3
Sales/Revenue/Turnover
106
158
246
240
295
334
708
- -
Operating Margin (%)
1.42
1.45
4.27
12.24
2.75
8.76
12.9
- -
Depreciation Expense
- -
- -
1
1
1
1
12
- -
Net Income, GAAP
- -
2
8
20
2
20
41
- -
Effective Tax Rate (%)
73.19
26.03
26.01
25.54
61.92
23.35
20.87
- -
Profit Margin (%)
0.35
1.05
3.16
8.5
0.77
6.01
5.81
- -
Working Capital
24
24
37
47
173
226
330
226
LT Debt
23
23
31
20
35
57
120
57
Total Equity
1
3
11
31
142
216
296
216
Return on Invested Capital (%)
- -
6.61
21.85
39.17
2.31
8.24
21.87
- -
Return on Capital (%)
- -
6.84
22.96
43.63
2.41
8.22
2.81
- -
Return on Common Equity (%)
- -
78.01
113.7
97.63
2.61
13.15
22.41
- -

Capital Structure

INR

•

in mil. unless spec.
Jun'24
Sep'24
Mar'25
ST Debt
1
- -
63
LT Borrowings
33
- -
57
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
3
5
Market Capitalization
- -
- -
277

Working Capital

INR

•

in mil. unless spec.
Jun'24
Sep'24
Mar'25
Total Current Assets
167
- -
536
Cash, Cash Equivalents & STI
6
- -
17
Accounts Receivable, Net
96
- -
364
Inventories
57
- -
96
Total Current Liabilities
99
- -
309
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
63
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
179.8%
36.96%
Free Cash Flow
- -
1,669.1%
-588.49%
Net Income, GAAP
- -
267.45%
105.27%
Sales/Revenue/Turnover
- -
40.3%
112.1%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
295
2025
- -
- -
334
2026
- -
- -
708

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.56
2025
- -
- -
3.62
2026
- -
- -
9.59

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nikhilkumar Y. Thakkar
Full Time Employees
210
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Office No. 4, 3rd Floor, Solitaire, Near Divya Bhaskar Press, S.G. Highway Ahmedabad GU India 380051
IPO Date
Nov 20, 2023
Website
sunrestlifescience.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sunrest Lifescience Ltd. (SUNREST.NS) markets and distributes over-the-counter (OTC) pharmaceutical and personal care products in India. The company offers a diverse portfolio spanning tablets, capsules, soft gels, syrups, dry syrups, ointments, creams, powders, gels, mouthwashes, solutions, suspensions, and toothpastes across therapeutic categories including anti-bacterials, antibiotics, anti-amoebics, anti-fungals, analgesics, neuropathy treatments, anti-hypertensives, anti-inflammatories, anti-ulcerants, anti-cold and anti-cough remedies, anti-allergics, nutritionals, multivitamins, multimineral nutraceuticals, anti-diarrheals, anti-malarials, anti-diabetics, dental care, anti-protozoals, anti-histamines, anti-lipidemic drugs, anti-parasitics, Ayurvedic formulations, and cosmetics. It primarily sources products from third-party manufacturers, including a 9.90% equity stake in Trilend Pharmaceuticals Private Limited, and partners with 32 manufacturers across India to serve wholesalers and retailers. Founded in 2017 and headquartered in Ahmedabad, Gujarat, the company began operations in its home state before expanding to Maharashtra in 2018 and Rajasthan in 2019, establishing a distribution network exceeding 250 distributors and 25,000 retailers supported by over 130 sales representatives. Sunrest Lifescience operates within the healthcare and pharmaceuticals industry, targeting OTC generic and branded products for general consumer markets in these regions. In recent developments, the company converted from a private limited entity to a public limited company in March 2023, enabling its initial public offering on the NSE Emerge platform to fund market expansion and operational growth. It shifted its registered office within Ahmedabad in August 2025 to support ongoing scalability. Financially, Sunrest Lifescience reported revenue growth to INR 33.12 crore for the fiscal year ended March 2025, with profits of INR 2.00 crore, reflecting compounded sales growth of 12% over the trailing twelve months despite high debtor days of 165. No major acquisitions, partnerships, or new product launches were announced in the last 1-2 years, with focus remaining on enhancing distribution and product portfolio efficiency.